enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bi-specific T-cell engager - Wikipedia

   en.wikipedia.org/wiki/Bi-specific_T-cell_engager

   Epcoritamab, sold under the brand name Epkinly, is used for the treatment of diffuse large B-cell lymphoma. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager. Epcoritamab is a bispecific CD20-directed CD3 T-cell engager.

3. MOPP (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/MOPP_(chemotherapy)

   MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)

4. Category:Chemotherapy regimens used in lymphoma - Wikipedia

   en.wikipedia.org/wiki/Category:Chemotherapy...

   Pages in category "Chemotherapy regimens used in lymphoma" The following 22 pages are in this category, out of 22 total. This list may not reflect recent changes .

5. ICE (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/ICE_(chemotherapy)

   ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.

6. Dacarbazine - Wikipedia

   en.wikipedia.org/wiki/Dacarbazine

   Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. [3] For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. [3] It is given by injection into a vein. [3]

7. EPOCH (chemotherapy) - Wikipedia

   en.wikipedia.org/wiki/EPOCH_(chemotherapy)

   EPOCH is an intensive chemotherapy regimen intended for treatment of aggressive non-Hodgkin's lymphoma. [1] [2] It is often combined with rituximab. In this case it is called R-EPOCH or EPOCH-R. The R-EPOCH regimen consists of: Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant;

8. Blinatumomab - Wikipedia

   en.wikipedia.org/wiki/Blinatumomab

   Blinatumomab linking a T cell to a malignant B cell.. Blinatumomab is a bispecific T-cell engager (BiTE). [7] It enables a patient's T cells to recognize malignant B cells. A molecule of blinatumomab combines two binding sites: a CD3 site for T cells and a CD19 site for the target B cells.

9. Clinical Lymphoma, Myeloma & Leukemia - Wikipedia

   en.wikipedia.org/wiki/Clinical_Lymphoma,_Myeloma...

   It was established as Clinical Lymphoma in 2000, renamed to Clinical Lymphoma & Myeloma in 2005 and obtained its current name in 2010. The journal covers research on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia, and related disorders, including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.